Toronto, April 13, 2018 (GLOBE NEWSWIRE) -- Dr. Rafi Hofstein, President and CEO of MaRS Innovation (MI) announced today that as part of Toronto Health Innovation Week, MI will lead a special health innovation and investment mission to Seoul, South Korea from May 9 to May 11, 2018. Representatives from 14 Ontario research institutions and innovation companies from life sciences and healthcare sectors will participate in the mission.
Exporting Ontario’s world-class innovations, technologies and expertise to new, fast-growing markets around the world ...
TORONTO, ON--(Marketwired - April 18, 2017) - MaRS Innovation (MI) and its South Korean partner, Korea Health Industry Development Institute (KHIDI), continue to build on the five-year global partnership agreement signed in December 2016 during Premier Wynne's mission to the Republic of Korea.
Together with Minister Moridi, Ontario Minister of Research, Innovation and Science, Rafi Hofstein, CEO of MI, is in Seoul to further the joint research initiatives first envisaged last year. Five outstanding Ontario scientists from some of MI's Member institutions are ...
TORONTO (February 13, 2017): QD Solar, a Canadian technology company created by MaRS Innovation and the University of Toronto, announced today the closing of a C$2.5M Series A funding led by DSM Venturing, with matching investment participation from existing investors, MaRS innovation and KAUST Innovation Fund.
The development of this technology is also supported by project funding that was announced in March 2016 from Sustainable Development Technology Canada (SDTC) through a C$2.5M grant, and through the generous support of the Ontario Research ...
Applications for next MSc PoP granting round being accepted until February 25, 2016
TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children.
Applications for the next MSc PoP granting round are open until March 4, 2016. To ...
February 4, 2016
in BresoTec Inc., Funding or Fundraising-Announcements, Government Partners, Licenseable Technologies, Member Institutions, News, Partnerships, Portfolio, St. Michael's Hospital, Start-Up Companies, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), University Health Network, University of Toronto
BresoTec, formerly known as ApneaDx, also among top five finalists
TORONTO, August 11, 2015 – Legworks' next-generation prosthetic knee took first place in Ontario Centres of Excellence’s (OCE’s) Parapan Am Games-affiliated Accessibility Tech Pitch competition. The company immediately said it would use the $20,000 award to fit 200 amputees in developing countries with its device.
Legworks was selected from 18 participants in a two-day elimination pitch competition – one of the features of the Government of Ontario’s Accessibility Innovation Showcase held at MaRS ...
August 19, 2015
in Awards, BresoTec Inc., Government Partners, Holland Bloorview Kids Rehabilitation Hospital, International Projects, Media Coverage, Member Institutions, News, Partnerships, Portfolio, Start-Up Companies
The Medical Sciences Proof-of-Principle (MSc PoP) program, administered by Ontario Centres of Excellence on behalf of Ontario's Ministry of Research & Innovation, is a province-wide initiative for which MaRS Innovation accepts applications from our 15 member institutions.
MaRS Innovation is currently recruiting applications for the July 30, 2015 August 27, 2015 (2 pm) deadline; for submissions to be considered via MI, paperwork must be in byAugust 24, 2015 (4 pm).
We've also learned there will be a second call for MScPoP applications in ...
CQDM and MaRS Innovation investing in new Encycle project to determine rules for making peptide drugs orally bioavailable
PHILADELPHIA (June 16, 2015) — FiercePharma has predicted that the pharmaceutical industry stands to lose $44 billion in drugs going off patent in 2015. The industry is searching for new therapeutics to replenish their pipelines while tackling existing and new drug receptor targets within the cell, improve patient care and lower administrative costs. In this context, drugs that can be orally swallowed, known as ...
June 16, 2015
in Encycle Therapeutics, Funding or Fundraising-Announcements, Government Partners, Industry Partners, Member Institutions, News, Partnerships, Portfolio, Start-Up Companies, University of Toronto
Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies
TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer's disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million ...
June 16, 2015
in Centre for Addiction and Mental Health (CAMH), Funding or Fundraising-Announcements, Government Partners, Industry Partners, Media Coverage, Member Institutions, News, Partnerships, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), University Health Network, University of Toronto
Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, announced October 15, 2014 that its project in partnership with the University of Toronto was successful in securing funding from Genome Canada under the Genomic Applications Partnership Program (GAPP).
The funding, announced by the Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, is part of 12 selected projects under Genome Canada’s Genomic Applications ...
TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC).
Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company's founding investors.
This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity.
Today's financing builds on prior ...